While FIT remains widely utilized globally, the newest results of Cologuard Plus show major improvements in biomolecular testing with the aid of NGS; mSEPT9 exhibits promising potential as a biomarker, although further studies are warranted to ascertain its superiority; MLH-1 is being developed for the detection of colon adenomas and CRC through stool-based DNA testing, while galectins are also under investigation for CRC screening. This evidence concerns the gene MLH1 and colon adenoma.